BlueStar

By Dave Muoio 02:51 pm June 3, 2020
WellDoc's BlueStar chronic disease-management tool has picked up another 510(k) FDA clearance that will allow it to support adult Type 2 diabetes patients using long-acting basal insulin. The feature was announced by WellDoc this morning, but cleared by the agency in April, according to a listing on its website. The new capability takes the form of a new program within the prescription BlueStar...
By Dave Muoio 04:06 pm March 12, 2020
Together in perfect harmony. Dexcom and Welldoc have kicked off a new collaboration that will provide Dexcom G6 continuous glucose monitor users with data-analysis insights from Welldoc's digital diabetes management product, BlueStar. These insights include information on how lifestyle factors such as activity, nutrition, sleep and medication adherence are affecting a user's glucose levels. “Now...
By Dave Muoio 03:12 pm November 21, 2019
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday. To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
By Dave Muoio 12:00 pm November 5, 2019
Type 1 diabetes management and CGM integration are now on the table for WellDoc’s BlueStar, a management platform well known for being the first mobile health product to secure reimbursement as a diabetes therapy. Thanks to a new FDA clearance, the company’s seventh, BlueStar will include integrated glucose level insights related to food, medication and activity that are based on the data from...
By Laura Lovett 02:19 pm July 2, 2018
The NHS is looking to ramp up its patient data security, after signing a contract with software company Privitar for its de-identification technology. The new technology will help prevent a person’s identify from being connected to their information.  “The health and care landscape is rapidly changing, and we can improve individual patient care if our systems can deliver a complete picture of...
By Dave Muoio 11:17 am April 18, 2018
Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform. The partnership is hoping to engage 10,000 diabetes patients on Sempre’s platform within 2018. “Looking at some of the metrics that Sempre has been able to provide...
By Dave Muoio 02:50 pm March 6, 2018
Samsung Health users will now have access to a new consumer-grade version of WellDoc’s digital diabetes management platform, the two companies announced this morning. The Diabetes Wellness Program is a 12-week wellness program designed to help Type 2 diabetes patients improve unhealthy behaviors and better manage their condition. The program is available through the Samsung Health version 5.14 or...
By Laura Lovett 10:21 am January 17, 2018
WellDoc’s digital diabetes management therapeutic BlueStar will now be available on the Solera network as a diabetes management option. Phoenix, Arizona-based Solera Health, a platform which offers a marketplace for chronic disease management programs, and digital therapeutic maker WellDoc announced the partnership today, and said that the partnership aligns both companies' goals to improve the...
By Heather Mack 05:41 pm April 19, 2017
Baltimore, Maryland-based WellDoc, which makes a digital platform for chronic disease management, is teaming up with consumer electronics giant Samsung to offer an integrated tool for people living with diabetes. BlueStarC will be available directly to consumers under Samsung’s newly launched mobile health app Samsung Health (formerly known as S Health). The diabetes management app is the third...
By Heather Mack 11:31 am March 31, 2017
In the first quarter of 2017, we tracked seven digital health-related FDA clearances. While the list isn’t long, it’s varied and relatively novel – from app and device integrations for diabetes treatment to a vest that maps cardiac rhythms. The beginning of this year also rang in some big changes, as the Trump Administration took root and nominated Dr. Scott Gottlieb as FDA deputy commissioner....